drugset / Trial / NCT05640713
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) in adult patients with B cell malignancies after failure of autologous chimeric antigen receptor T- cell(CAR-T) therapy in china.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-02-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART19A | Cell therapy | — | Other |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |